MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

84.29 -1.87

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

82.91

Максимум

85.92

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+59.22% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-492M 5.9B
Предишно отваряне	86.16
Предишно затваряне	84.29

Настроения в новините

By Acuity

91%

7 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 17:04 ч. UTC

Значими двигатели на пазара

FDA Rejects Replimune's Melanoma Drug for a Second Time

11.04.2026 г., 00:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Big Yachts, Big Bucks -- Barrons.com

10.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10.04.2026 г., 21:01 ч. UTC

Печалби

Cango Inc.: Files Annual Report on Form 20-F With SEC

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 20:31 ч. UTC

Пазарно говорене

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10.04.2026 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

10.04.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10.04.2026 г., 18:25 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Finish With Weekly Gains -- Market Talk

10.04.2026 г., 18:05 ч. UTC

Пазарно говорене

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10.04.2026 г., 17:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10.04.2026 г., 17:26 ч. UTC

Печалби

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10.04.2026 г., 17:10 ч. UTC

Пазарно говорене

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10.04.2026 г., 17:00 ч. UTC

Значими събития в новините

Construction Business Taking a Hit From Iran Conflict -- WSJ

10.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

10.04.2026 г., 16:12 ч. UTC

Печалби

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10.04.2026 г., 16:11 ч. UTC

Печалби

Partners Group: Traditional Programs Contributed $3.3B

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group 1Q New Client Demand $8.3B

10.04.2026 г., 16:09 ч. UTC

Печалби

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10.04.2026 г., 15:54 ч. UTC

Придобивния, сливания и поглъщания

Plenitude Completes Acquisition of Acea Energia

10.04.2026 г., 15:38 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

59.22% нагоре

12-месечна прогноза

Среден 137.14 USD 59.22%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

7 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.